Cetuximab was approved by the Food and Drug Administration (FDA) for use against metastatic colorectal cancer in February 2004 (5) and first gained approval in Europe for use in the treatment of EGFR-expressing metastatic colorectal cancer following the failure of irinotecan-containing regimens (6). The gene discussed is EGFR; the disease is metastatic colorectal cancer.